Search

The article from New York University (NYU) discusses the use of intravenous (IV) digoxin loading doses for rate control of atrial arrhythmias in critically ill patients. The study aimed to assess the safety and effectiveness of digoxin loading doses and the serum digoxin concentrations achieved. Results showed that a median total digoxin loading dose of 750 mcg targeting a serum digoxin concentration < 1.5 ng/mL may be considered for acute rate control in critically ill patients with atrial fibrillation/atrial flutter. Further research is needed to confirm these findings. [Extracted from the article]

The article highlights a study from the All India Institute of Medical Sciences (AIIMS) on digoxin-induced syncope and related complications. Topics discussed include the risks associated with digoxin toxicity, particularly in the context of chronic kidney disease, the case of an elderly patient with bradycardia and myocardial infarction, and the importance of dose adjustment to prevent toxicity.

A recent study conducted by researchers at Azienda Ospedaliera Universitaria Integrata has focused on the condition of hyperkalemia, which is characterized by bradycardia, renal failure, atrioventricular (AV) node blocking, shock, and hyperkalemia. The study presented a case of a 66-year-old female patient who exhibited symptoms of digoxin toxicity, including fatigue, bradycardia, anuria, and hypotension. Despite attempts to manage the condition, the patient required renal dialysis and digoxin immune fab administration. The researchers emphasized the importance of promptly managing this life-threatening condition and considering potential coexisting manifestations of drug intoxication. [Extracted from the article]

A recent study conducted at the National University Heart Center in Singapore explored the use of adjunctive cardioprotective therapy during percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). The study involved 22 patients who were randomized into two groups: an active group that received a combination therapy of Milrinone and Esmolol, and a placebo group that received saline infusion. The results showed that patients in the placebo group had higher improvement in infarct size compared to those in the active group. Further research is needed to assess the results of scar regression. [Extracted from the article]

A new study conducted at Sir Ganga Ram Hospital in New Delhi, India compared the effects of two drugs, levosimendan and milrinone, in managing low cardiac output after the arterial switch operation in infants weighing up to 3 kg. The study found that levosimendan was as safe and effective as milrinone in treating low cardiac output syndrome. Additionally, levosimendan was found to be renal protective compared to milrinone. The study provides valuable insights into the use of these drugs in neonatal cardiac care. [Extracted from the article]

This document provides information about a clinical trial, NCT06409533, that aims to evaluate the effectiveness of different heart rate control strategies in patients with atrial fibrillation associated with rheumatic mitral stenosis. The trial will compare lenient rate control (resting heart rate <110 bpm) to strict rate control (resting heart rate <80 bpm) and assess outcomes such as hospitalizations, quality of life, and functional capacity. The study will involve standardized pharmacological treatment and regular follow-ups to monitor participants' progress. The trial is currently recruiting participants in Indonesia and is expected to be completed by December 2024. [Extracted from the article]

A researcher from Harefield Hospital has developed a new hybrid protocol for detecting inducible ischemia, a condition where blood flow to the heart is restricted. The protocol combines low-dose dobutamine infusion with supine bicycle exercise to achieve target heart rate. The study found that the protocol was safe, feasible, and had a high success rate in achieving the target heart rate. The findings suggest that this new protocol could be a valuable tool in diagnosing ischemia. [Extracted from the article]

Researchers from Ocean University of China have conducted a study on the optimization of anti-heart failure medication milrinone. The study focuses on the design and assembly of a ternary salt cocrystal of milrinone using gallic acid and 3,5-dinitrobenzoic acid. The researchers found that the ternary salt cocrystal significantly improved the solubility and permeability of milrinone compared to the parent medicine. This research provides a new cocrystalline model for milrinone and demonstrates the potential of ternary salt cocrystals in modifying the properties of anti-heart failure medicines. [Extracted from the article]

This article discusses a study that aimed to measure the time-dependent effects of dobutamine on the modulations of cardiac activity in rats. The researchers adapted a method for rat cardiac analysis and compared it with standard measures of sympathetic and parasympathetic activity estimation. The results showed that the adapted method accurately depicted sympathetic reactivity induced by dobutamine administration, resembling autonomic alterations observed during physical exercise. The findings suggest that this method could be useful for future clinical and translational studies involving rodents, particularly in investigating the relationship between changes in cardiac activity and brain dynamics in cases involving neurodegeneration, brain injuries, and cardiovascular conditions. [Extracted from the article]

A new report from Marburg, Germany presents fresh data on the impact of inotropic drugs on patients with acute decompensated heart failure (HF). The study included fifty patients with different causes of HF who were treated with either dobutamine or levosimendan. The researchers found that patients with dilated cardiomyopathy (DCM), those who received levosimendan therapy, and those with sinus rhythm/pacemaker lead rhythm (SR/PM) seemed to benefit the most from inotropic therapy. The study concluded that positive inotropic therapy can be beneficial for patients with acute decompensated HF, particularly those with DCM, after levosimendan therapy, and with SR/PM. [Extracted from the article]

A recent study conducted by the Karolinska Institute in Stockholm, Sweden, examined the use of digoxin in patients with heart failure with reduced ejection fraction (HFrEF), both with and without atrial fibrillation (AF). The study found that digoxin use was associated with lower mortality and morbidity in patients with AF, but higher mortality and morbidity in patients without AF. The research analyzed data from the Swedish Heart Failure Registry and included over 42,000 patients with HFrEF. The study's findings contribute to the ongoing debate surrounding the use of digoxin in heart failure treatment. [Extracted from the article]

A recent study conducted by researchers at Indiana University School of Medicine examined the use of intravenous milrinone therapy in ambulatory patients with advanced heart failure. The study found that long-term use of milrinone was associated with improvements in cardiac index, New York Heart Association class, liver function, and tolerance of medical therapy. Additionally, patients who received milrinone for six months or longer experienced a decrease in hospitalization days and improved tolerance of beta blocker therapy. The findings suggest that long-term ambulatory intravenous milrinone therapy may be beneficial for patients with advanced heart failure. [Extracted from the article]

A recent study conducted by researchers at the Arctic University of Norway (UiT) investigated the effects of different drugs on human cardiomyocytes during hypothermia. The study found that milrinone and isoprenaline increased the risk of ventricular arrhythmias during hypothermia, while levosimendan did not pose the same risk. Levosimendan was identified as a promising candidate for inotropic treatment of hypothermic patients due to its ability to treat hypothermia-induced cardiac dysfunction without increasing the risk of ventricular arrhythmias. This research provides valuable insights into potential treatment strategies for patients with accidental hypothermia. [Extracted from the article]

Keywords: Cardiac Stressing Agents; Cardiology; Cardiovascular; Cardiovascular Agents; Cardiovascular Diseases and Conditions; Catecholamines; Diagnosis; Diagnostic Techniques and Procedures; Dobutamine; Dobutamine Therapy; Doppler Echocardiography; Drugs and Therapies; Echocardiography; Health and Medicine; Heart Disease; Heart Disorders and Diseases; Heart Failure; Inotropic Agents; Pharmaceuticals; Phenethylamines; Radiologic Adjuncts; Radiologic Agents; Vasopressors EN Cardiac Stressing Agents Cardiology Cardiovascular Cardiovascular Agents Cardiovascular Diseases and Conditions Catecholamines Diagnosis Diagnostic Techniques and Procedures Dobutamine Dobutamine Therapy Doppler Echocardiography Drugs and Therapies Echocardiography Health and Medicine Heart Disease Heart Disorders and Diseases Heart Failure Inotropic Agents Pharmaceuticals Phenethylamines Radiologic Adjuncts Radiologic Agents Vasopressors 591 591 1 10/03/23 20231003 NES 231003 2023 OCT 2 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- New research on heart failure is the subject of a new report. Cardiac Stressing Agents, Cardiology, Cardiovascular, Cardiovascular Agents, Cardiovascular Diseases and Conditions, Catecholamines, Diagnosis, Diagnostic Techniques and Procedures, Dobutamine, Dobutamine Therapy, Doppler Echocardiography, Drugs and Therapies, Echocardiography, Health and Medicine, Heart Disease, Heart Disorders and Diseases, Heart Failure, Inotropic Agents, Pharmaceuticals, Phenethylamines, Radiologic Adjuncts, Radiologic Agents, Vasopressors Among the imaging modalities, dobutamine stress echocardiography has come a long way in establishing itself as a feasible, safe, effective, relatively cheap non-invasive technique. [Extracted from the article]

Keywords: Houston; State:Texas; United States; North and Central America; Antiarrhythmic Agents; Cardiovascular Agents; Clinical Research; Clinical Trials and Studies; Digoxin Therapy; Drugs and Therapies; Group V Antiarrhythmics; Health and Medicine; Heart Disorders and Diseases; Heart Failure; Inotropic Agents; Pharmaceuticals EN Houston State:Texas United States North and Central America Antiarrhythmic Agents Cardiovascular Agents Clinical Research Clinical Trials and Studies Digoxin Therapy Drugs and Therapies Group V Antiarrhythmics Health and Medicine Heart Disorders and Diseases Heart Failure Inotropic Agents Pharmaceuticals 261 261 1 09/04/23 20230904 NES 230904 2023 SEP 4 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Investigators discuss new findings in Heart Disorders and Diseases - Heart Failure. Houston, State:Texas, United States, North and Central America, Antiarrhythmic Agents, Cardiovascular Agents, Clinical Research, Clinical Trials and Studies, Digoxin Therapy, Drugs and Therapies, Group V Antiarrhythmics, Health and Medicine, Heart Disorders and Diseases, Heart Failure, Inotropic Agents, Pharmaceuticals. [Extracted from the article]

Birmingham, United Kingdom, Europe, Aminopyridines, Amrinone, Cardiology, Cardiomyopathies, Cardiotonic, Cardiovascular, Cardiovascular Agents, Cardiovascular Diseases and Conditions, Dilated Cardiomyopathy, Drugs and Therapies, Health and Medicine, Heart Disease, Heart Disorders and Diseases, Heart Failure, Inotropic Agents, Milrinone, Milrinone Therapy, Pediatrics, Pharmaceuticals, Vasodilator Agents Keywords: Birmingham; United Kingdom; Europe; Aminopyridines; Amrinone; Cardiology; Cardiomyopathies; Cardiotonic; Cardiovascular; Cardiovascular Agents; Cardiovascular Diseases and Conditions; Dilated Cardiomyopathy; Drugs and Therapies; Health and Medicine; Heart Disease; Heart Disorders and Diseases; Heart Failure; Inotropic Agents; Milrinone; Milrinone Therapy; Pediatrics; Pharmaceuticals; Vasodilator Agents EN Birmingham United Kingdom Europe Aminopyridines Amrinone Cardiology Cardiomyopathies Cardiotonic Cardiovascular Cardiovascular Agents Cardiovascular Diseases and Conditions Dilated Cardiomyopathy Drugs and Therapies Health and Medicine Heart Disease Heart Disorders and Diseases Heart Failure Inotropic Agents Milrinone Milrinone Therapy Pediatrics Pharmaceuticals Vasodilator Agents 374 374 1 04/17/23 20230417 NES 230417 2023 APR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Investigators discuss new findings in Heart Disorders and Diseases - Dilated Cardiomyopathy. Keywords for this news article include: Birmingham, United Kingdom, Europe, Aminopyridines, Amrinone, Cardiology, Cardiomyopathies, Cardiotonic, Cardiovascular, Cardiovascular Agents, Cardiovascular Diseases and Conditions, Dilated Cardiomyopathy, Drugs and Therapies, Health and Medicine, Heart Disease, Heart Disorders and Diseases, Heart Failure, Inotropic Agents, Milrinone, Milrinone Therapy, Pediatrics, Pharmaceuticals, Vasodilator Agents, Department of Pediatric Cardiology. [Extracted from the article]

Keywords: Durham; State:North Carolina; United States; North and Central America; Aminopyridines; Amrinone; Arrhythmia; Cardiac Arrhythmias; Cardiac Surgery; Cardiology; Cardiotonic; Cardiovascular Agents; Drug Administration Routes; Drugs and Therapies; Health and Medicine; Heart Disorders and Diseases; Hospitals; Inotropic Agents; Intravenous Infusions; Kidney; Milrinone; Milrinone Therapy; Nephrology; Parenteral Infusions; Pharmaceuticals; Risk and Prevention; Vasodilator Agents EN Durham State:North Carolina United States North and Central America Aminopyridines Amrinone Arrhythmia Cardiac Arrhythmias Cardiac Surgery Cardiology Cardiotonic Cardiovascular Agents Drug Administration Routes Drugs and Therapies Health and Medicine Heart Disorders and Diseases Hospitals Inotropic Agents Intravenous Infusions Kidney Milrinone Milrinone Therapy Nephrology Parenteral Infusions Pharmaceuticals Risk and Prevention Vasodilator Agents 137 137 1 03/27/23 20230327 NES 230327 2023 MAR 27 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Researchers detail new data in Heart Disorders and Diseases - Cardiac Arrhythmias. Of the 197 patients who met inclusion, there was no difference in the presence of new arrhythmias (42.9% v 40.3%, p = 0.76) or in the time to first new arrhythmia from milrinone initiation in those with renal impairment compared to those without renal impairment (29.1 hours v 33.3 hours, p = 0.54). [Extracted from the article]